The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 14, 2021

Filed:

Apr. 16, 2021
Applicant:

Windtree Therapeutics, Inc., Warrington, PA (US);

Inventors:

Giuseppe Bianchi, Milan, IT;

Patrizia Ferrari, Varese, IT;

Mara Ferrandi, Milan, IT;

Paolo Barassi, Castelveccana, IT;

Assignee:

Windtree Therapeutics, Inc., Warrington, PA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 495/04 (2006.01); C07D 519/00 (2006.01); A61K 31/5685 (2006.01); A61P 9/06 (2006.01); A61P 9/04 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5685 (2013.01); A61K 9/009 (2013.01); A61P 9/04 (2018.01); A61P 9/06 (2018.01);
Abstract

Compositions for intravenous infusion of istaroxime, or a metabolite of istaroxime, in human patients suffering from heart failure are disclosed. Likewise, methods for extended infusion of istaroxime or its metabolites in individuals with heart failure are disclosed. In particular, some methods disclosed herein include the infusion of istaroxime, or a metabolite thereof, for a period of time that is greater than six hours in order to improve cardiac relaxation without triggering arrhythmogenic events in an individual suffering from heart failure. Other methods include administration of istaroxime until certain plasma concentration thresholds of istaroxime metabolites are achieved. Also disclosed are istaroxime metabolites with selective SERCA2a activation.


Find Patent Forward Citations

Loading…